Assessment of fatigue in adult patients with sickle cell disease: Use of the functional assessment of chronic illness therapy-Fatigue (FACIT-fatigue) questionnaire.
FACIT
fatigue
quality of life
sickle cell disease
sleep quality
stress
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
20
03
2024
accepted:
15
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
aheadofprint
Résumé
Few studies have used validated scales to assess the intensity and determinants of fatigue, a major symptom of sickle cell disease (SCD). We aimed to assess the level of basal fatigue in adult patients with SCD, using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. We prospectively included 102 stable adult outpatients with SCD over 2 months, who answered the FACIT-Fatigue (ranging from 0 (worst imaginable fatigue) to 52 (no fatigue)) and reported on the intensity of fatigue and its impact on quality of life. The cut-off for significant fatigue was <34. The median [IQR] FACIT-Fatigue score was 29 [22-37], indicating moderate-to-severe fatigue. In a multivariate analysis, the FACIT-Fatigue score was significantly associated with female sex, high body mass index, high level of stress, poor sleep quality, and number of previous episodes of acute chest syndrome, but not with the genotype or the haemoglobin level. Most adult patients with SCD experience significant and sometimes intense fatigue; this is probably due to several factors, including disease activity. Fatigue should be evaluated systematically during consultations and in patient education programmes and as an end-point in therapeutic trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: a lancet Haematology commission. Lancet Haematol. 2023;10(8):e633–e686.
Osunkwo I, Andemariam B, Minniti CP, Inusa BPD, el Rassi F, Francis‐Gibson B, et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: results from the international sickle cell world assessment survey (SWAY). Am J Hematol. 2021;96(4):404–417.
Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, et al. Health‐related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203–205.
Harris KM, Preiss L, Varughese T, Bauer A, Calhoun CL, Treadwell M, et al. Examining mental health, education, employment, and pain in sickle cell disease. JAMA Netw Open. 2023;6(5):e2314070.
Sogutlu A, Levenson JL, McClish DK, Rosef SD, Smith WR. Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES project. Psychosomatics. 2011;52(3):272–279.
Machado MO, Kang NYC, Tai F, Sambhi RDS, Berk M, Carvalho AF, et al. Measuring fatigue: a meta‐review. Int J Dermatol. 2021;60(9):1053–1069.
Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol rheumatoid arthritis fatigue multi‐dimensional questionnaire (BRAF MDQ), Bristol rheumatoid arthritis fatigue numerical rating scales (BRAF NRS) for severity, effect, and coping, Chalder fatigue questionnaire (CFQ), checklist individual strength (CIS20R and CIS8R), fatigue severity scale (FSS), functional assessment chronic illness therapy (fatigue) (FACIT‐F), multi‐dimensional assessment of fatigue (MAF), multi‐dimensional fatigue inventory (MFI), pediatric quality of life (PedsQL) multi‐dimensional fatigue scale, profile of fatigue (ProF), short form 36 vitality subscale (SF‐36 VT), and visual analog scales (VAS). Arthritis Care Res (Hoboken). 2011;63(S11):S263–S286.
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia‐related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74.
Montan I, Löwe B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (Facit)‐fatigue scale. Value Health. 2018;21(11):1313–1321.
Butt Z, Lai J s, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the functional assessment of chronic illness therapy—fatigue (FACIT‐F) scale. J Psychosom Res. 2013;74(1):64–68.
Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the functional assessment of chronic illness therapy‐fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021;5(1):27.
Cella D, Lai J s, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–538.
Keller S, Yang M, Treadwell MJ, Hassell KL. Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ‐MeSM. Health Qual Life Outcomes. 2017;15(1):117.
Azizoddin DR, Gandhi N, Weinberg S, Sengupta M, Nicassio PM, Jolly M. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus. 2019;28(2):163–173.
Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, et al. The impact of tofacitinib on fatigue, sleep, and health‐related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from phase 3 trials. Arthritis Res Ther. 2022;24(1):1–17.
Taher AT, Musallam KM, Viprakasit V, Kattamis A, Lord‐Bessen J, Yucel A, et al. Psychometric evaluation of the NTDT‐PRO questionnaire for assessing symptoms in patients with non‐transfusion‐dependent beta‐thalassaemia. BMJ Open. 2023;13(3):e066683.
Knisely MR, Pugh N, Kroner B, Masese R, Gordeuk V, King AA, et al. Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: report from the sickle cell disease implementation consortium. Am J Hematol. 2020;95(9):1066–1074.
Hildenbrand AK, Quinn CT, Mara CA, Peugh JL, McTate EA, Britto MT, et al. A preliminary investigation of the psychometric properties of PROMIS® scales in emerging adults with sickle cell disease. Health Psychol. 2019;38(5):386–390.
Singh SA, Bakshi N, Mahajan P, Morris CR. What is the future of patient reported outcomes in sickle cell disease? Expert Rev Hematol. 2020;13(11):1165–1173.
McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50.
Van't Leven M, Zielhuis GA, van der Meer JW, Verbeek AL, Bleijenberg G. Fatigue and chronic fatigue syndrome‐like complaints in the general population. Eur J Public Health. 2010;20(3):251–257.
Ameringer S, Elswick RK, Smith W. Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health‐related quality of life. J Pediatr Oncol Nurs. 2014;31(1):6–17.
Krogstad H, Loge JH, Grotmol KS, Kaasa S, Kiserud CE, Salvesen Ø, et al. Symptoms in the general Norwegian adult population ‐ prevalence and associated factors. BMC Public Health. 2020;20(1):988.
Acaster S, Dickerhoof R, DeBusk K, Bernard K, Strauss W, Allen LF. Qualitative and quantitative validation of the FACIT‐fatigue scale in iron deficiency anemia. Health Qual Life Outcomes. 2015;13:60.
Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, el‐Beshlawy A, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.
Brown C, Idowu M, Drachtman R, Beaubrun A, Agodoa I, Nguyen A, et al. Patient‐reported experiences in voxelotor‐treated children and adults with sickle cell disease: a semistructured interview study. Biomed Res Int. 2023;2023:7533111.
Dovern E, Nijland SJAM, van Muilekom MM, Suijk LMJ, Hoogendoorn GM, Mekelenkamp H, et al. Physical, mental, and social health of adult patients with sickle cell disease after allogeneic hematopoietic stem cell transplantation: a mixed‐methods study. Transplant Cell Ther. 2023;29(4):283.e1–283.e283. e9.